Edition:
United Kingdom

BB Biotech AG (BION.S)

BION.S on Swiss Exchange

65.75CHF
19 Jul 2019
Change (% chg)

CHF-1.05 (-1.57%)
Prev Close
CHF66.80
Open
CHF66.75
Day's High
CHF66.75
Day's Low
CHF65.45
Volume
71,947
Avg. Vol
74,443
52-wk High
CHF74.60
52-wk Low
CHF55.05

About

BB Biotech AG is a Switzerland-based investment company, which principal activity is to invest in companies active in the biotechnology industry. BB Biotech AG invests mainly in companies operating in such sectors as oncology, infectious diseases, cardiovascular diseases, metabolic diseases and autoimmune diseases. The Company’s... (more)

Overall

Beta: 1.16
Market Cap(Mil.): CHF3,731.19
Shares Outstanding(Mil.): 55.40
Dividend: 2.75
Yield (%): 4.08

Financials

  BION.S Industry Sector
P/E (TTM): 4.38 69.41 32.67
EPS (TTM): 15.37 -- --
ROI: 28.44 8.94 14.49
ROE: 28.44 10.07 15.79

Italy - Factors to watch on July 19

The following factors could affect Italian markets on Friday.

19 Jul 2019

BRIEF-BB Biotech H1 Net Profit At CHF 554 Mln

* CONSOLIDATION LEAVES A MARK ON RESULTS IN THE SECOND QUARTER

19 Jul 2019

DIARY - Italy to August 31

Inclusion of diary items does not necessarily mean that Reuters will file a story based on the event.

10 Jul 2019

DIARY - Italy to August 31

Inclusion of diary items does not necessarily mean that Reuters will file a story based on the event.

08 Jul 2019

DIARY - Italy to August 31

Inclusion of diary items does not necessarily mean that Reuters will file a story based on the event.

05 Jul 2019

BRIEF-BB Biotech Q1 Profit Of CHF 890 Million

* Q1 PROFIT OF CHF 890 MN (PROFIT OF CHF 28 MN IN CORRESPONDING PERIOD OF PREVIOUS YEAR) Source text for Eikon: Further company coverage: (Gdynia Newsroom)

26 Apr 2019

Swiss stocks - Factors to watch on April 12

ZURICH/BERLIN, April 12 The Swiss blue-chip SMI was seen opening 0.1 percent lower at 9,543 points on Friday, according to premarket indications by bank Julius Baer .

12 Apr 2019

BRIEF-BB Biotech Launches New Buyback Program

* SAID ON THURSDAY CONCLUDES ITS SHARE BUYBACK PROGRAM AND LAUNCHES A NEW BUYBACK PROGRAM

12 Apr 2019

BRIEF-BB Biotech FY Net Result Swings To Loss Of CHF 471 Million

* FY NET LOSS OF CHF 471 MN COMPARED TO A NET GAIN OF CHF 688 MN FOR FULL YEAR OF 2017 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

15 Feb 2019

Earnings vs. Estimates